• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Treatment of Feline Pemphigus Foliaceus in General Practice

August 28, 2018
Natalie Stilwell, DVM, MS, PhD

A retrospective study showed that, while remission rates were high, immunosuppressive therapy rarely cured the dermatologic disorder.

The autoimmune disorder feline pemphigus foliaceus (PF) typically causes dermatologic lesions on the face, ears, and paws. Immunosuppressive therapy, including glucocorticoids, cyclosporine, and chlorambucil, is commonly used to treat the disorder, and typically remission is observed with treatment.

Because the majority of existing literature focuses on PF treatment by veterinary specialists, researchers retrospectively studied disease outcome for cats treated in primary care practices. Their findings were recently published in Journal of Small Animal Practice.

RELATED:

  • Antibiotic Selection in Pyoderma
  • Understanding Skin Disease in Cats

Diagnosis and Clinical Signs

Forty-three cases of histologically confirmed feline PF were identified via email surveys from Veterinary Information Network members. Cases occurred in the United States, Canada, United Kingdom, Italy, Australia, and New Zealand. Most cases were domestic shorthair cats, all were spayed or neutered, and the median age of PF onset was 6 years.

Advertisement

Most cats were diagnosed within 2 months of first exhibiting clinical signs consistent with PF. The most common dermatologic lesion sites were the ears, haired areas of the face, and nail beds. Bilaterally symmetric crusts were most common, although paronychia, erosions, and alopecia were each reported in over half of the cats. Approximately half of the cats were also lethargic and/or pruritic. All dermatophyte cultures and tests were negative.

Treatment and Outcome

Eighty-eight percent of the 43 cats received systemic antibiotic treatment before being administered immunosuppressive therapies. Thirty-one cats received glucocorticoid therapy alone, while 11 received a combination of glucocorticoids and cyclosporine. Prednisolone was the most commonly prescribed glucocorticoid with a median dose of 2.2 mg/kg/day, and most cats received the oral rather than injectable form. The median dose of cyclosporine was 7 mg/kg/day.

Follow-up information was available for 40 cats. Of these, PF went into remission for 90% that were treated with glucocorticoids alone and for 73% receiving combination therapy. Use of a higher prednisolone dose offered no additional therapeutic benefit compared with lower doses. Also, use of cyclosporine did not significantly affect disease remission outcome. PF relapsed in 73% of cats after initial remission, necessitating continued or altered treatment. Maintenance therapy was continued for 28 cats, 18 of which received altered treatment regimens consisting of the addition or removal of glucocorticoids and/or cyclosporine.

Disease outcome information, available for 38 cats, was as follows:

  • PF was cured and medication was discontinued for 4 cats.
  • 25 cats went into sustained remission but continued to receive immunosuppressive therapy.
  • 3 cats died of PF-related causes.
  • 3 cats died of causes unrelated to PF.
  • 3 cats were referred to specialty practices for continued PF management.

Eleven cats experienced 1 or more glucocorticoid-related adverse effects, including polyuria and polydipsia, corneal ulceration, diabetes mellitus, hepatotoxicity, and intestinal hemorrhage. Adverse effects were more frequent with administration of injectable than oral glucocorticoids.

Summary

While remission rate was high for cats treated for PF in primary practice, relapse was also common. Also, approximately 25% of cats developed adverse effects from long-term immunosuppressive therapy.

Dr. Stilwell received her DVM from Auburn University, followed by a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida. She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.

Related Content:

Dermatology
Comparing treatments for restoring the skin barrier in atopic dogs
Comparing treatments for restoring the skin barrier in atopic dogs
Exploring molecular allergology as the future of allergy testing and immunotherapy
Exploring molecular allergology as the future of allergy testing and immunotherapy
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards

Advertisement

Latest News

What's new with the "Dentistry Lane" across the veterinary profession?

Meet the BlackDVM Network

Study finds certain canine breeds should be screened for cancer at young ages

AVMA releases 2 videos informing pet parents on pet dental care

View More Latest News
Advertisement